stocks logo

CTOR

Citius Oncology Inc
$
1.530
-0.07(-4.375%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.720
Open
1.600
VWAP
1.59
Vol
579.13K
Mkt Cap
119.91M
Low
1.520
Amount
920.97K
EV/EBITDA(TTM)
--
Total Shares
78.37M
EV
123.71M
EV/OCF(TTM)
--
P/S(TTM)
--
Citius Oncology, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing targeted oncology therapies. The Company’s lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy. It is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria toxin fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. After uptake into the cell, the diphtheria toxin (DT) fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death.
Show More
1 Analyst Rating
up Image
96.08% Upside
Wall Street analysts forecast CTOR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTOR is 3.00 USD with a low forecast of 3.00 USD and a high forecast of 3.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
1 Hold
0 Sell
Hold
up Image
96.08% Upside
Current: 1.530
sliders
Low
3.00
Averages
3.00
High
3.00
Maxim
Buy
to
Hold
downgrade
2025-05-23
Reason
Maxim downgraded Citius Oncology to Hold from Buy.
Maxim Group
Michael Okunewitch
Strong Buy
Initiates
$3
2024-11-27
Reason
Maxim initiated coverage of Citius Oncology with a Buy rating and $3 price target.
EF Hutton
Jason Kolbert
Strong Buy
Maintains
$6
2024-08-13
Reason

Valuation Metrics

The current forward P/E ratio for Citius Oncology Inc (CTOR.O) is -8.00, compared to its 5-year average forward P/E of -2.14. For a more detailed relative valuation and DCF analysis to assess Citius Oncology Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.14
Current PE
-8.00
Overvalued PE
1.89
Undervalued PE
-6.16

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1.07
Current PS
3.28
Overvalued PS
3.04
Undervalued PS
-0.90

Financials

Annual
Quarterly
FY2025Q2
0.00
Total Revenue
FY2025Q2
YoY :
+1845.87%
-7.47M
Operating Profit
FY2025Q2
YoY :
-3164.05%
-7.74M
Net Income after Tax
FY2025Q2
YoY :
-375.00%
-0.11
EPS - Diluted
FY2025Q2
YoY :
-100.00%
N/A
Free Cash Flow

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

CTOR News & Events

Events Timeline

2025-07-15 (ET)
2025-07-15
08:36:27
Citius Oncology signs distribution agreement for Lymphir with Cencora
select
2025-07-14 (ET)
2025-07-14
08:38:19
Citius Oncology files to sell $15M of common stock, warrants
select
2025-06-17 (ET)
2025-06-17
08:10:20
Citius Oncology expects commercial launch of Lymphir in second half of 2025
select
Sign Up For More Events

News

8.5
07-17PRnewswire
Citius Oncology Announces Closing of $9.0 Million Public Offering
8.5
07-16Newsfilter
Citius Oncology Announces Pricing of $9.0 Million Public Offering
7.5
07-15Newsfilter
Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora
Sign Up For More News

FAQ

arrow icon

What is Citius Oncology Inc (CTOR) stock price today?

The current price of CTOR is 1.53 USD — it has decreased -4.38 % in the last trading day.

arrow icon

What is Citius Oncology Inc (CTOR)'s business?

arrow icon

What is the price predicton of CTOR Stock?

arrow icon

What is Citius Oncology Inc (CTOR)'s revenue for the last quarter?

arrow icon

What is Citius Oncology Inc (CTOR)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Citius Oncology Inc (CTOR)'s fundamentals?

arrow icon

How many employees does Citius Oncology Inc (CTOR). have?

arrow icon

What is Citius Oncology Inc (CTOR) market cap?